SMARCA4 and neoplasm: TILs therapy may represent a novel approach for rhabdoid tumors, as TILs could recognize specific aberrations in SWI/SNFc, such as complete loss of SMARCA4 or SMARCB1 or other neoantigens created by epigenetic changes occurring within the tumor.